Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: firstname.lastname@example.org
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Mali's first Ebola case, a 2-yr-old girl, dies -officials
25 Oct 2014 at 12:47am
By Adama Diarra and Tiemoko Diallo BAMAKO (Reuters) - A two-year-old girl who was Mali's first case of Ebola died on Friday, shortly after the World Health Organization warned that many people had potentially been exposed to the virus because she was taken across the country while ill. The girl had travelled with her grandmother hundreds of kilometres by bus from Guinea via Mali's capital to the western town of Kayes, where she was diagnosed on Thursday. Health workers were scrambling to trace hundreds of potential contacts in a bid to prevent Ebola taking hold in Mali. ...
Dallas nurse receives thanks, hug from Obama
24 Oct 2014 at 11:40pm
BETHESDA, Md. (AP) ? A nurse who caught Ebola while caring for a Dallas patient who died of the disease walked out of a Washington-area hospital virus-free Friday and into open arms.
Two U.S. states to quarantine health workers returning from Ebola zones
24 Oct 2014 at 7:31pm
By Ellen Wulfhorst and David Morgan NEW YORK/WASHINGTON (Reuters) - New York and New Jersey will automatically quarantine medical workers returning from Ebola-hit West African countries and the U.S. government is considering the same step after a doctor who treated patients in Guinea came back infected, officials said on Friday. The steps announced by the two states, which go beyond the current restrictions being imposed by President Barack Obama's administration on travelers from Liberia, Sierra Leone or Guinea, came as medical detectives tried to retrace the steps in New York City of Dr. ...
Rules for returning Ebola health workers need coordination: U.S. official
24 Oct 2014 at 7:03pm
WASHINGTON (Reuters) - Top Obama administration officials met on Friday morning to discuss potential new rules for healthcare workers returning to the United States after treating Ebola patients in West Africa, but they want any measures to be coordinated, a senior official said. "We will not hesitate to take any action that we feel has the potential to fortify us against additional imported Ebola cases," said the official, who spoke on condition of anonymity. ...
NY, NJ order Ebola quarantine for doctors, others
24 Oct 2014 at 7:02pm
NEW YORK (AP) ? Mayor Bill de Blasio (dih BLAH'-zee-oh) says a team of disease detectives tracking the movements of a New York City doctor diagnosed with Ebola will soon detail their findings.
Two US states order tough Ebola quarantine rules
24 Oct 2014 at 6:53pm
New York and New Jersey ordered mandatory quarantine for medics who treated victims of Ebola in West Africa, after the deadly virus spread to America's largest city. The new measures were ordered by state governors Andrew Cuomo and Chris Christie the day after an American doctor tested positive for Ebola one week after returning from working in hard-hit Guinea. Craig Spencer, 33, was in stable condition in isolation at Bellevue Hospital Center on Friday as he underwent treatment for the illness, which has killed nearly 4,900 people -- most of them in West Africa.
At least four dead in escape bid at Dominican Republic jail
24 Oct 2014 at 5:30pm
By Manuel Jimenez SANTO DOMINGO (Reuters) - At least four prisoners were killed and nine others wounded, including two guards, after an attempted mass escape at a prison in the southern Dominican Republic, officials said on Friday. Guards opened fire on inmates at the Najayo jail in San Cristobal, about 22 miles (35 km) south of Santo Domingo, after the prison was attacked by armed men in a black SUV, according to law enforcement and prison officials in the Caribbean nation. No prisoners managed to escape, prison officials said. ...
Rollins, Konerko named Clemente Award winners
24 Oct 2014 at 5:20pm
SAN FRANCISCO (Reuters) - Former Chicago White Sox player Paul Konerko and Jimmy Rollins of the Philadelphia Phillies were named co-winners of the Roberto Clemente Award on Friday for their community work. "Paul Konerko and Jimmy Rollins are two of baseball's great ambassadors and have long distinguished themselves as leaders both on the field and in their communities," said Major League Baseball commissioner Bud Selig said. "Their commitment to making a difference in the lives of children is a wonderful reflection of the legacy Roberto Clemente has left on our game and in society. ...
Baseball-Rollins, Konerko named Clemente Award winners
24 Oct 2014 at 5:13pm
Former Chicago White Sox player Paul Konerko and Jimmy Rollins of the Philadelphia Phillies were named co-winners of the Roberto Clemente Award on Friday for their community work. "Paul Konerko and Jimmy Rollins are two of baseball's great ambassadors and have long distinguished themselves as leaders both on the field and in their communities," said Major League Baseball commissioner Bud Selig said. "Their commitment to making a difference in the lives of children is a wonderful reflection of the legacy Roberto Clemente has left on our game and in society." Both have been heavily involved in helping children. Konerko, who retired this season, founded the Bring Me Home Campaign in 2007 with former teammate Jim Thome and their respective wives, and have raised nearly $500,000 for school supplies and back-to-school clothing.
Therapists missed Newtown gunman's rage as a teenager: report
24 Oct 2014 at 4:47pm
By Richard Weizel HARTFORD Conn. (Reuters) - The extent of Newtown school shooter Adam Lanza's growing rage, isolation and delusions when he was a teenager were apparently overlooked by his mother, psychiatrists and counselors, according to a report expected to be issued next month. The report found that Lanza, who gunned down 20 children and six educators at the Sandy Hook Elementary School nearly two years ago, did not have to become a violent adult, Scott Jackson, chairman of the Sandy Hook Advisory Commission, said on Friday. ...
Mali's first Ebola case, a two-year-old girl, dies: officials
24 Oct 2014 at 4:15pm
By Adama Diarra and Tiemoko Diallo BAMAKO (Reuters) - A two-year-old girl who was Mali's first case of Ebola died on Friday, shortly after the World Health Organization warned that many people had potentially been exposed to the virus because she was taken across the country while ill. The girl had traveled with her grandmother hundreds of kilometers by bus from Guinea via Mali's capital to the western town of Kayes, where she was diagnosed on Thursday. Health workers were scrambling to trace hundreds of potential contacts in a bid to prevent Ebola taking hold in Mali. ...
NY doctor with Ebola a serious student with funny side, friends say
24 Oct 2014 at 4:01pm
By Ellen Wulfhorst NEW YORK (Reuters) - The young doctor diagnosed with Ebola in New York City is a big-hearted man with a serious interest in international emergency medicine and a flair for languages, yet his friends call him "a goofball." Craig Spencer, originally from the Detroit area, has specialized in International Emergency Medicine at the highly respected Columbia University-New York Presbyterian Hospital since 2011, according to his online LinkedIn resume. ...
New York City to check daily with people returning from West Africa
24 Oct 2014 at 3:30pm
NEW YORK (Reuters) - New York City's health department will actively monitor anyone who arrives in the city from one of the three West African countries affected by Ebola, Mayor Bill de Blasio said at a news conference on Friday. He said health officials would make daily checks on those people, typically by telephone, for 21 days after their return to make sure they are not displaying Ebola symptoms, in keeping with new protocols by the U.S. Centers for Disease and Control and Prevention. (Reporting by Frank McGurty; Editing by James Dalgleish)
CDC guidelines 'insufficient' for New York population density: Cuomo
24 Oct 2014 at 3:30pm
NEW YORK (Reuters) - Federal guidelines for screening and monitoring travelers from Ebola-affected countries are "insufficient" for the New York City region with its extreme population density, New York Governor Andrew Cuomo said on Friday. As part of stepped up measures to prevent the disease from spreading in the New York area, all medical workers traveling from the three most affected West African countries and arriving at airports in the New York area will face automatic quarantine for 21 days, Cuomo said at a joint press conference with New Jersey Governor Chris Christie. ...
U.S. military starts training its Ebola rapid-response team
24 Oct 2014 at 3:16pm
By Jim Forsyth SAN ANTONIO (Reuters) - As health officials were trying to manage a patient infected with Ebola in New York, U.S. military personnel in Texas were in the first stages of training a new rapid-response team that could head to hospitals the next time an outbreak occurs. The 30-member U.S. Military Ebola Rapid Response Team assembled at the Army's San Antonio Military Medical Center on Wednesday and consists of five physicians, 20 nurses and five certified trainers. The group will supervise treatment and help hospitals deal with the intricacies of treating Ebola. ...